InMed Pharmaceuticals, Inc. (INM)
1.41
-0.02
(-1.40%)
USD |
NASDAQ |
Aug 25, 11:42
InMed Pharmaceuticals Shareholders Equity (Quarterly) : 6.892M for March 31, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | 6.892M |
| December 31, 2025 | 9.588M |
| September 30, 2025 | 11.59M |
| June 30, 2025 | 13.43M |
| March 31, 2025 | 7.022M |
| December 31, 2024 | 6.182M |
| September 30, 2024 | 8.395M |
| June 30, 2024 | 9.206M |
| March 31, 2024 | 11.10M |
| December 31, 2023 | 12.77M |
| September 30, 2023 | 9.578M |
| June 30, 2023 | 12.09M |
| March 31, 2023 | 12.39M |
| December 31, 2022 | 14.34M |
| September 30, 2022 | 11.01M |
| June 30, 2022 | 9.078M |
| March 31, 2022 | 10.89M |
| December 31, 2021 | 14.17M |
| September 30, 2021 | 15.22M |
| June 30, 2021 | 7.377M |
| March 31, 2021 | 10.41M |
| December 31, 2020 | 5.958M |
| September 30, 2020 | 4.201M |
| June 30, 2020 | 5.878M |
| March 31, 2020 | 6.772M |
| Date | Value |
|---|---|
| December 31, 2019 | 9.316M |
| September 30, 2019 | 11.32M |
| June 30, 2019 | 13.95M |
| March 31, 2019 | 16.23M |
| December 31, 2018 | 17.64M |
| September 30, 2018 | 19.90M |
| June 30, 2018 | 20.62M |
| March 31, 2018 | 11.40M |
| December 31, 2017 | 11.48M |
| September 30, 2017 | 5.914M |
| June 30, 2017 | 6.134M |
| March 31, 2017 | 3.088M |
| December 31, 2016 | 1.51M |
| September 30, 2016 | 0.95M |
| June 30, 2016 | 0.7577M |
| March 31, 2016 | 0.5026M |
| December 31, 2015 | 0.7167M |
| September 30, 2015 | 0.9228M |
| June 30, 2015 | 1.268M |
| March 31, 2015 | 0.8992M |
| December 31, 2014 | 0.9002M |
| September 30, 2014 | 1.260M |
| June 30, 2014 | 1.522M |
| March 31, 2014 | -0.1787M |
| December 31, 2013 | -0.0896M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| NervGen Pharma Corp. | 12.18M |
| Milestone Pharmaceuticals, Inc. | 18.22M |
| Clearmind Medicine, Inc. | 11.49M |
| Lexaria Bioscience Corp. | 4.738M |
| Target Group, Inc. (Canada) | -8.655M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 9.134M |
| Total Liabilities (Quarterly) | 2.242M |
| Debt to Equity Ratio | 0.061 |
| Current Ratio | 3.115 |
| Net Debt Paydown Yield | 4.95% |